Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
Globe Newswire•04/11/2026•11:45 ET
2
Key Highlights
- ➤Valneva will report nine-month 2026 financial results on November 24, 2026
- ➤Live webcast begins at 3 p.m. CET/9 a.m. ET with business update
- ➤Valneva markets three proprietary travel vaccines
- ➤Valneva’s Lyme disease vaccine candidate is under regulatory review with Pfizer
Lyon (France), November 4, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its nine-month 2026 financial results on Tuesday, November 24, 2026.
The Company will host a live webcast beginning at 3 p.m. CET/9 a.m. ET to discuss the financial results and provide a business update.
Get started
Create a free account to read the full story.